Rocket Pharmaceuticals, Inc. (RCKT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Rocket Pharmaceuticals (RCKT) CEO Gaurav Shah presented at the Morgan Stanley Global Healthcare Conference, emphasizing the company's dual-platform gene therapy approach with an increasing focus on in vivo AAV cardiac programs. Shah highlighted three specific rare cardiac conditions—Danon disease, PKP2-arrhythmogenic, and BAG3 dilated cardiomyopathies—which collectively target a substantial patient population of at least 100,000 across the U.S. and Europe, underscoring a strategic pursuit of high-impact therapeutic areas despite the individual rarity of each disease.

Analysis

Rocket Pharmaceuticals (RCKT) is positioning itself as a dual-platform gene therapy company with a clear strategic pivot towards its in vivo AAV cardiac programs, moving from its initial focus on ex vivo lentiviral hematology. CEO Gaurav Shah highlighted that the company's disclosed pipeline now includes six programs, with a significant emphasis on three cardiac assets targeting Danon disease, PKP2-arrhythmogenic cardiomyopathy, and BAG3 dilated cardiomyopathy. This cardiac portfolio is strategically designed to address a broad spectrum of cardiomyopathies (hypertrophic, arrhythmogenic, and dilated). Critically, management frames the market opportunity by aggregating these individually rare diseases, estimating a combined addressable patient population of at least 100,000 in the U.S. and Europe. This narrative turns a collection of niche indications into a substantial commercial opportunity. Furthermore, the CEO's reference to a new, undisclosed pipeline of cardiac assets suggests potential for future expansion and news flow, reinforcing the company's commitment to becoming a leader in cardiac gene therapy.

Key Decisions for Investors

• Investors should focus on the AAV cardiac portfolio—specifically the Danon, PKP2, and BAG3 programs—as management has explicitly defined this as the company's primary strategic growth area.
• The investment thesis relies on the company's ability to execute its strategy of aggregating multiple rare diseases; therefore, consider the total addressable market of 100,000+ patients as a key metric for evaluating the long-term commercial potential.
• Monitor for future announcements regarding the new, undisclosed pipeline of cardiac assets, as this represents a potential near-term catalyst and an indicator of the company's ongoing innovation.
• Given the strategic shift, investors should weigh the heightened concentration of risk and reward in the cardiac AAV platform relative to the more diversified, dual-platform approach previously emphasized.